St. Jude Research/Supplemental Data/ALL4/Table 2

	Supplementary Information for:
	Gene-expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment. Amy Holleman, Meyling H. Cheok, Monique L. den Boer, Wenjian Yang, Anjo J.P. Veerman, Karin M. Kazemier, Deqing Pei, Cheng Cheng, Ching-Hon Pui, Mary V. Relling, Gritta E. Janka-Schaub, Rob Pieters, and William E. Evans

Supplemental Table 2 : Patient characteristics.

Included were 173 patients categorized as resistant or sensitive to one or more of the four drugs. The sample size and the distribution of known prognostic factors (i.e., white blood cell count (WBC) and age at diagnosis; gender, and lineage) for each antileukemic agent are shown for (a) all patients and (b) the B-lineage ALL patients.

Drug		N	Age at diagnosis [median in years]	Gender	WBC at diagnosis [10⁹/L]	Lineage
Prednisolone	Sensitive Resistant	66 27	5.9 8.0 P=0.007*	36M 30F 17M 10F P=0.497^‡	43.0 19.9 P=0.314*	54B 12T 20B 7T P=0.408^‡
Vincristine	Sensitive Resistant	89 36	6.0 6.7 P=0.651*	54M 35F 20M 16F P=0.689^‡	34.7 15.4 P=0.172*	75B 14T 29B 7T P=0.606^‡
asparaginase	Sensitive Resistant	81 45	4.4 7.3 P=0.004*	47M 34F 24M 21F P=0.708^‡	30.0 28.3 P=0.729*	66B 15T 40B 5T P=0.320^‡
Daunorubicin	Sensitive Resistant	94 28	4.6 7.7 P=0.031*	57M 37F 17M 11F P=1.0^‡	40.0 17.6 P=0.378*	82B 12T 23B 5T P=0.537^‡

Drug		N	Age at diagnosis [median in years]	Gender	WBC at diagnosis [10⁹/L]
Prednisolone	Sensitive Resistant	54 20	5.8 8.9 P=0.016*	28M 26F 12M 8F P=0.605^‡	33.1 8.3 P=0.012*
Vincristine	Sensitive Resistant	75 29	6.0 6.3 P=0.888*	46M 29F 15M 14F P=0.358^‡	25.6 9.9 P=0.016*
asparaginase	Sensitive Resistant	66 40	4.2 7.3 P=0.003*	38M 28F 21M 19F P=0.688^‡	23.2 18.5 P=0.732*
Daunorubicin	Sensitive Resistant	82 23	4.4 7.2 P=0.117*	49M 33F 13M 10F P=0.814^‡	26.8 16.3 P=0.275*

M=male, F=female; P-values determined by *Wilcoxon rank sum test ^‡Fisher’s exact test